The Collagen Stimulation Mechanism — A Deeper Look at How Biostimulatory Treatments Actually Work
As biostimulatory treatments become an increasingly central part of aesthetic practice, understanding the biological mechanisms behind them is not merely academic. It informs better clinical decisions, more honest patient conversations, and a more rigorous approach to treatment planning. Here is a deep-dive into some underlying science.
Why collagen matters — and why we lose it
Collagen is the most abundant structural protein in the human body, accounting for approximately 75% of the dry weight of skin. It is produced primarily by fibroblasts, the principal cells of the dermis, and exists in several distinct types; type I collagen provides tensile strength and structural integrity, while type III collagen, more elastic in nature, predominates in younger skin and in the early stages of wound healing. Together, they form the extracellular matrix that gives skin its firmness, resilience, and capacity to recover from deformation.
From the third decade of life onwards, collagen production declines at a rate of approximately 1% per year. This is compounded by a reduction in fibroblast activity, degradation of existing collagen by matrix metalloproteinases, and the cumulative effects of ultraviolet exposure, which accelerates collagen breakdown and impairs synthesis. The clinical consequences are well recognised: thinning of the skin, loss of structural support, reduction in skin elasticity, and the progressive changes in volume and texture that characterise the ageing face.
The foreign body response as a therapeutic tool
The central mechanism by which the most established biostimulators work is, at first glance, counterintuitive. Rather than delivering collagen directly, they exploit the body's own inflammatory response to drive new collagen synthesis. When a biostimulatory agent such as Sculptra (poly-L-lactic acid PLLA) is introduced into the tissue, the immune system recognises it as a foreign body and mounts a controlled inflammatory response. This is not a side effect to be minimised; it is the therapeutic event.
The inflammatory reaction initiates the deposition of type III collagen fibres around the microspheres of the material, followed by a fibroblastic tissue response and peripheral type I collagen deposition. This mechanism continues for weeks until there is remodelling of type III collagen with predominance of type I collagen in the newly formed tissue, resulting in improved dermal thickness and quality PubMed Central.
This transition from type III to type I collagen mirrors the maturation process seen in normal wound healing, and it is this maturing collagen matrix that accounts for the gradual but durable improvement in skin quality that characterises a well-delivered biostimulatory treatment.
The molecular pathways involved
Research into the precise molecular mechanisms has advanced considerably in recent years. Sculptra (PLLA) induces collagen synthesis through a complex, inflammation-dependent foreign body reaction involving M2 macrophage polarisation, activation of the TGF-β/Smad pathway, mechano-transduction via Piezo1 channels, and lactate-mediated signalling Brazilian Journal of Health Review. Each of these pathways contributes to the activation and sustained activity of fibroblasts, the cells ultimately responsible for synthesising new collagen.
The TGF-β/Smad pathway is particularly significant. Transforming growth factor beta is a cytokine released by macrophages during the inflammatory response, and it acts as a powerful upstream regulator of extracellular matrix gene expression, promoting the synthesis of collagen types I, III, IV, and V from fibroblasts. Understanding this pathway helps to explain both why biostimulatory results take time to develop and why they tend to be durable; the collagen that is produced is the product of a sustained cellular process rather than an immediate mechanical correction.
Sculptra (PLLA) — the evidence base
PLLA filler was approved in aesthetics in 1999 in Europe, with collagen stimulatory properties first evidenced in humans in subjects who received PLLA injections across three sessions spaced four weeks apart, with collagen histochemical determination confirmed on biopsies taken at different time points PubMed Central. This early human evidence established the foundational principle that has since been validated across a substantial body of peer-reviewed literature: that controlled, repeated stimulation produces progressive and measurable neocollagenesis.
Importantly, the durability of the PLLA response is well documented. Results have been demonstrated to persist for up to 25 months following treatment, distinguishing it meaningfully from hyaluronic acid fillers, which are metabolised within months and provide no lasting structural benefit to the tissue itself.
How different biostimulators compare
While PLLA remains the most extensively researched biostimulator, other agents work through related but distinct mechanisms. Calcium hydroxyapatite (CaHA) stimulates collagen production through direct fibroblast activation on contact with its microspheres, as well as through macrophage-mediated pathways similar to those seen with PLLA. Polycaprolactone (PCL) has been shown to activate a specific transcriptional axis that promotes collagen maturation.
While all three agents effectively promote neo-collagenesis, they do so through fundamentally different biological pathways Brazilian Journal of Health Review; a distinction that has practical implications for patient selection, treatment planning, and the management of adverse events.
Polynucleotides, increasingly used in aesthetic practice, operate through a different mechanism again; promoting tissue repair and fibroblast proliferation through their interaction with cellular receptors, with an emerging evidence base that continues to expand.
Clinical implications
An understanding of the collagen stimulation mechanism has direct relevance to clinical practice. It explains why biostimulatory treatments require a series of sessions rather than a single appointment; each session adds to the cumulative stimulus, and the biological response unfolds over the months that follow. It explains why results continue to improve after treatment has concluded, and why appropriate intervals between sessions are clinically important rather than merely conventional. It also informs the honest patient conversation about expectations: these treatments work with the body's own biology, at the body's own pace, and the results they produce are proportionally more natural and more durable for it.
The science, in short, supports what experienced clinicians have observed in practice for years. Biostimulatory treatment is not a shortcut or a substitute for a more considered approach to facial ageing. It is, when properly understood and properly delivered, one of the most elegant applications of regenerative biology that aesthetic medicine currently has to offer.
In Summary
The TGF-β/Smad pathway in particular is fascinating when you dig into it. The fact that what is essentially a controlled foreign body reaction, something we would ordinarily want to minimise, turns out to be the precise mechanism driving one of the most durable and natural-looking treatments in aesthetic medicine is a beautiful piece of biology
It also makes a compelling case for why these treatments need time and why rushing the process undermines the science.
The views expressed in Clinical Perspectives are the author's own and reflect their personal and professional experience in aesthetic medicine.
Scientific References
Bernardo RTR et al. Effect of poly-L-lactic acid and polydioxanone biostimulators on type I and III collagen biosynthesis. Skin Research and Technology. 2024;30:e13681. https://doi.org/10.1111/srt.13681
Brazilian Journal of Health Review. Mechanistic aspects of collagen biostimulators: calcium hydroxyapatite, poly-L-lactic acid and polycaprolactone. 2025. https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/84742
Vleggaar D et al. Collagen Stimulators in Body Applications: A Review Focused on Poly-L-Lactic Acid (PLLA). Clinical, Cosmetic and Investigational Dermatology. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9233565/
Ferreira ACM et al. Efficacy, Durability, and Safety of Collagen Biostimulators Based on PLLA and CaHA in the Face: A Systematic Review. Aesthetic Plastic Surgery. 2025. https://link.springer.com/article/10.1007/s00266-025-05412-8
MDPI Pharmacy. Injectable Biostimulator in Adipose Tissue: An Update and Literature Review. 2025. https://www.mdpi.com/2218-0532/93/4/62